Axsome Therapeutics, Inc.
AXSM
$210.63
$2.811.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -191.64M | -188.30M | -183.17M | -229.53M | -246.90M |
| Total Depreciation and Amortization | 9.94M | 9.30M | 9.06M | 8.86M | 8.51M |
| Total Amortization of Deferred Charges | 642.00K | 795.00K | 1.30M | 1.85M | 2.36M |
| Total Other Non-Cash Items | 103.14M | 104.34M | 102.65M | 121.37M | 122.66M |
| Change in Net Operating Assets | 6.67M | 3.14M | -23.25M | -3.51M | -7.27M |
| Cash from Operations | -71.26M | -70.73M | -93.41M | -100.95M | -120.63M |
| Capital Expenditure | -700.00K | -263.00K | -480.00K | -439.00K | -471.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -700.00K | -263.00K | -480.00K | -439.00K | -471.00K |
| Total Debt Issued | 280.00M | 400.00M | 330.00M | 260.00M | 190.00M |
| Total Debt Repaid | -283.09M | -404.38M | -334.11M | -263.90M | -193.55M |
| Issuance of Common Stock | 118.25M | 107.10M | 127.46M | 124.02M | 131.94M |
| Repurchase of Common Stock | -14.02M | -12.08M | -7.11M | -6.60M | -6.23M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -12.35M | -15.45M | -14.78M | -14.19M | -13.70M |
| Cash from Financing | 88.79M | 75.19M | 101.47M | 99.32M | 108.46M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 16.83M | 4.20M | 7.58M | -2.07M | -12.64M |